Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.
Immunotherapy resistance
Oncolytic virus
Prostate cancer
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
29
04
2020
accepted:
30
09
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Prostate cancers are considered "cold" tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely responsible for the lack of sensitivity of prostate cancer patients to immune checkpoint blockade (ICB) therapy. Oncolytic virus therapy can potentially overcome this resistance to immunotherapy in prostate cancers by transforming cold tumors into "hot," immune cell-infiltrated tumors. We investigated whether the combination of intratumoral oncolytic reovirus, followed by targeted blockade of Programmed cell death protein 1 (PD-1) checkpoint inhibition and/or the immunomodulatory CD73/Adenosine system can enhance anti-tumor immunity. Treatment of subcutaneous TRAMP-C2 prostate tumors with combined intratumoral reovirus and anti-PD-1 or anti-CD73 antibody significantly enhanced survival of mice compared with reovirus or either antibody therapy alone. Only combination therapy led to rejection of pre-established tumors and protection from tumor re-challenge. This therapeutic effect was dependent on CD4
Identifiants
pubmed: 33665363
doi: 10.1016/j.omto.2020.09.010
pii: S2372-7705(20)30149-2
pmc: PMC7900644
doi:
Types de publication
Journal Article
Langues
eng
Pagination
434-446Informations de copyright
© 2020 The Authors.
Références
Trends Immunol. 2012 May;33(5):231-7
pubmed: 22487321
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Clin Cancer Res. 2009 Jul 1;15(13):4374-4381
pubmed: 19509134
J Clin Oncol. 2018 Jun 10;36(17):1658-1667
pubmed: 28981385
Cancers (Basel). 2018 Jun 15;10(6):
pubmed: 29914097
Viruses. 2015 Dec 01;7(12):6251-78
pubmed: 26633466
Clin Cancer Res. 2010 Nov 15;16(22):5564-72
pubmed: 20926400
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Leukemia. 2018 Jan;32(1):230-233
pubmed: 28832023
Nat Med. 1997 Jun;3(6):625-31
pubmed: 9176488
PLoS One. 2013 Oct 29;8(10):e77991
pubmed: 24205056
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Mol Ther. 2007 Aug;15(8):1522-30
pubmed: 17457318
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
BMC Cancer. 2011 Jun 06;11:221
pubmed: 21645351
Mol Ther. 2014 Oct;22(10):1851-63
pubmed: 24957982
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Clin Cancer Res. 2008 Nov 15;14(22):7358-66
pubmed: 19010851
Clin Cancer Res. 2013 Oct 15;19(20):5626-35
pubmed: 23983257
Cancer Gene Ther. 2010 Jan;17(1):69-70
pubmed: 19590528
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Mol Ther. 2016 Feb;24(1):166-74
pubmed: 26310630
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cancer Immunol Immunother. 2003 Sep;52(9):535-45
pubmed: 14627125
Mol Ther Oncolytics. 2019 Apr 25;13:93-106
pubmed: 31080879
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
J Biomed Biotechnol. 2012;2012:485156
pubmed: 23125525
J Immunol. 2005 Mar 15;174(6):3377-85
pubmed: 15749870
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Clin Cancer Res. 2019 Oct 1;25(19):5818-5831
pubmed: 31273010
Nat Immunol. 2003 Jul;4(7):670-9
pubmed: 12796776
Nat Commun. 2017 Mar 27;8:14754
pubmed: 28345650
Front Oncol. 2014 Apr 10;4:74
pubmed: 24782985
Cancer Res. 2010 Mar 15;70(6):2435-44
pubmed: 20215509
Mol Ther. 2011 Apr;19(4):797-804
pubmed: 21245852
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
J Immunol. 2008 May 1;180(9):6018-26
pubmed: 18424722
Mol Ther Oncolytics. 2018 Feb 14;9:1-12
pubmed: 29989024
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
PLoS One. 2013 Oct 30;8(10):e77992
pubmed: 24205057
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Mol Cancer Ther. 2010 Nov;9(11):2924-33
pubmed: 20978162
BMC Cancer. 2012 Aug 24;12:368
pubmed: 22920673
Curr Opin Immunol. 2011 Apr;23(2):286-92
pubmed: 21185705
J Immunother. 2003 Nov-Dec;26(6):468-72
pubmed: 14595214
Cancer Gene Ther. 2012 Apr;19(4):282-91
pubmed: 22240921
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373